+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Risk factors associated with the cumulative survival of low-dose methotrexate in 273 Japanese patients with rheumatoid arthritis



Risk factors associated with the cumulative survival of low-dose methotrexate in 273 Japanese patients with rheumatoid arthritis



Journal of Clinical Rheumatology 13(2): 73-78



Methotrexate (MTX) has become the most commonly prescribed disease-modifying antirheumatic drug (DMARD) for the treatment of rheumatoid arthritis (RA). In the Western countries, the MTX dosage is safely increased to a maximum of 25 mg/wk until a significant response is observed. On the contrary, in Japan, MTX has been approved only as a second-line agent, and the approved maximum MTX dosage is only 8 mg/wk. This suboptimal dosage may affect MTX survival in Japanese RA patients. To study risk factors associated with the cumulative survival of MTX in Japanese RA patients. Data on 273 patients (male 44, female 229) with RA treated with MTX between January 1, 2000 and September 30, 2004 in our center were studied. Two hundred seventy-three patients were followed for 437 person-years of MTX exposure. Mean MTX dosage was 5.5 +/- 1.9 mg/wk. The cumulative MTX survival probability after 5 years was 61.9%. Univariate Cox regression analysis showed a significant correlation between MTX survival probability and use of fewer previous DMARDs, higher dose of MTX, inclusion of folate supplementation, and shorter disease duration. In the multivariate Cox regression model, use of fewer previous DMARDs remained significantly related to MTX survival. Reasons for discontinuation included adverse effects in 34 patients (12.5%) and inefficacy in 6 patients (2.2%). Cumulative survival was the same or slightly better than those in reports from Western countries, with less withdrawals reported due to adverse events or inefficacy. Whether these results are due to different MTX needs in Japanese or to acceptance of less clinical efficacy will require further studies. The use of fewer previous DMARDs was associated with longer MTX survival.

(PDF emailed within 0-6 h: $19.90)

Accession: 055579886

Download citation: RISBibTeXText

PMID: 17414533

DOI: 10.1097/01.rhu.0000260526.29331.a8


Related references

Association between cumulative methotrexate dose, non-invasive scoring system and hepatic fibrosis detected by Fibroscan in rheumatoid arthritis patients receiving methotrexate. International Journal of Rheumatic Diseases 2018, 2018

Liver stiffness correlates with methotrexate cumulative dose in patients with rheumatoid arthritis. Digestive and Liver Disease 44(2): 149-153, 2012

Genetic risk factors for drug-induced liver injury in rheumatoid arthritis patients using low-dose methotrexate. Pharmacogenomics 14(1): 63-73, 2013

Drug retention rates of second biologic agents after switching from tumor necrosis factor inhibitors for rheumatoid arthritis in Japanese patients on low-dose methotrexate or without methotrexate. Modern Rheumatology 25(2): 251-256, 2015

Treatment with low dose methotrexate in rheumatoid arthritis: Risk factors for serious side effects. Therapie 52(2): 111-116, 1997

Treatment with low dose methotrexate in rheumatoid arthritis: risk factors for severe complications. Therapie 52(2): 111-116, 1997

Effect of denosumab on Japanese patients with rheumatoid arthritis: a dose-response study of AMG 162 (Denosumab) in patients with RheumatoId arthritis on methotrexate to Validate inhibitory effect on bone Erosion (DRIVE)-a 12-month, multicentre, randomised, double-blind, placebo-controlled, phase II clinical trial. Annals of the Rheumatic Diseases 75(6): 983-990, 2017

Incidence and risk factors for serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: a report from the Registry of Japanese Rheumatoid Arthritis Patients for Longterm Safety. Journal of Rheumatology 38(7): 1258-1264, 2012

Influence of High-Dose Folic Acid on Methotrexate Efficacies and Safety in Japanese Rheumatoid Arthritis Patients. Drug Research 67(12): 705-709, 2017

Fatal Cytopenia Induced by Low-Dose Methotrexate in Elderly With Rheumatoid Arthritis. Identification of Risk Factors. American Journal of Therapeutics 24(1): E106-E107, 2016

Impact of methotrexate dose on efficacy of adalimumab in Japanese patients with rheumatoid arthritis: Results from registered data analyses. Modern Rheumatology 27(1): 15-21, 2016

Serum levels and pharmacodynamics of methotrexate and its metabolite 7-hydroxy methotrexate in Japanese patients with rheumatoid arthritis treated with 2-mg capsule of methotrexate three times per week. Modern Rheumatology 15(6): 405-409, 2006

Factors associated with toxicity, final dose, and efficacy of methotrexate in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases 62(5): 423-426, 2003

Arterial stiffness and cumulative inflammatory burden in rheumatoid arthritis: a dose-response relationship independent of established cardiovascular risk factors. Rheumatology 48(12): 1606-1612, 2010

Safety and effectiveness of high-dose methotrexate (over 8mg/week) in 2838 Japanese patients with rheumatoid arthritis: A postmarketing surveillance report. Modern Rheumatology: 1-12, 2017